Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation
Author:
Affiliation:
1. Department of Chemistry and ‡Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
Funder
Swiss National Science Foundation
Krebsliga Schweiz
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm5009242
Reference60 articles.
1. The Protein Kinase Complement of the Human Genome
2. Protein kinases — the major drug targets of the twenty-first century?
3. Kinase Inhibitor Drugs
4. Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
5. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Science and Art of Structure-Based Virtual Screening;ACS Medicinal Chemistry Letters;2024-03-25
2. Bioactive atropisomers: Unraveling design strategies and synthetic routes for drug discovery;Medicinal Research Reviews;2024-03-21
3. Biological Significance of EphB4 Expression in Cancer;Current Protein & Peptide Science;2024-03
4. Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer;Journal of Medicinal Chemistry;2023-12-26
5. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review;Current Medicinal Chemistry;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3